Correction: Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT)

John F R Robertson; Robert E Coleman; Kwok-Leung Cheung; Abigail Evans; Chris Holcombe; Anthony Skene; Daniel Rea; Samreen Ahmed; Ali Jahan; Kieran Horgan; Petra Rauchhaus; Roberta Littleford; S Y Amy Cheung; Marie Cullberg; Elza C de Bruin; Loumpiana Koulai; Justin P O Lindemann; Martin Pass; Paul Rugman; Gaia Schiavon; Rahul Deb; Pauline Finlay; Andrew Foxley; Julia M W Gee

doi:10.1158/1078-0432.CCR-22-3568

Correction: Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER⁺ invasive breast cancer (STAKT)

John F R Robertson
, Robert E Coleman
, Kwok-Leung Cheung
, Abigail Evans
, Chris Holcombe
, Anthony Skene
, Daniel Rea
, Samreen Ahmed
, Ali Jahan
, Kieran Horgan
, Petra Rauchhaus
, Roberta Littleford
, S Y Amy Cheung
, Marie Cullberg
, Elza C de Bruin
, Loumpiana Koulai
, Justin P O Lindemann
, Martin Pass
, Paul Rugman
, Gaia Schiavon

Rahul Deb, Pauline Finlay, Andrew Foxley, Julia M W Gee

Cancer Research UK Clinical Trials Unit

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English
Article number	5469
Number of pages	1
Journal	Clinical cancer research : an official journal of the American Association for Cancer Research
Volume	28
Issue number	24
DOIs	https://doi.org/10.1158/1078-0432.CCR-22-3568
Publication status	Published - 15 Dec 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1158/1078-0432.CCR-22-3568

Cite this

Robertson, J. F. R., Coleman, R. E., Cheung, K.-L., Evans, A., Holcombe, C., Skene, A., Rea, D., Ahmed, S., Jahan, A., Horgan, K., Rauchhaus, P., Littleford, R., Amy Cheung, S. Y., Cullberg, M., de Bruin, E. C., Koulai, L., Lindemann, J. P. O., Pass, M., Rugman, P., ... Gee, J. M. W. (2022). Correction: Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER⁺ invasive breast cancer (STAKT). Clinical cancer research : an official journal of the American Association for Cancer Research, 28(24), Article 5469. https://doi.org/10.1158/1078-0432.CCR-22-3568

@article{49832c5819ad4be8a0276d841cd2836d,

title = "Correction: Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT)",

author = "Robertson, \{John F R\} and Coleman, \{Robert E\} and Kwok-Leung Cheung and Abigail Evans and Chris Holcombe and Anthony Skene and Daniel Rea and Samreen Ahmed and Ali Jahan and Kieran Horgan and Petra Rauchhaus and Roberta Littleford and \{Amy Cheung\}, \{S Y\} and Marie Cullberg and \{de Bruin\}, \{Elza C\} and Loumpiana Koulai and Lindemann, \{Justin P O\} and Martin Pass and Paul Rugman and Gaia Schiavon and Rahul Deb and Pauline Finlay and Andrew Foxley and Gee, \{Julia M W\}",

year = "2022",

month = dec,

day = "15",

doi = "10.1158/1078-0432.CCR-22-3568",

language = "English",

volume = "28",

journal = "Clinical cancer research : an official journal of the American Association for Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research",

number = "24",

}

Robertson, JFR, Coleman, RE, Cheung, K-L, Evans, A, Holcombe, C, Skene, A, Rea, D, Ahmed, S, Jahan, A, Horgan, K, Rauchhaus, P, Littleford, R, Amy Cheung, SY, Cullberg, M, de Bruin, EC, Koulai, L, Lindemann, JPO, Pass, M, Rugman, P, Schiavon, G, Deb, R, Finlay, P, Foxley, A & Gee, JMW 2022, 'Correction: Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER⁺ invasive breast cancer (STAKT)', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 28, no. 24, 5469. https://doi.org/10.1158/1078-0432.CCR-22-3568

Correction: Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER⁺ invasive breast cancer (STAKT). / Robertson, John F R; Coleman, Robert E; Cheung, Kwok-Leung et al.
In: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, No. 24, 5469, 15.12.2022.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Correction

T2 - Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT)

AU - Robertson, John F R

AU - Coleman, Robert E

AU - Cheung, Kwok-Leung

AU - Evans, Abigail

AU - Holcombe, Chris

AU - Skene, Anthony

AU - Rea, Daniel

AU - Ahmed, Samreen

AU - Jahan, Ali

AU - Horgan, Kieran

AU - Rauchhaus, Petra

AU - Littleford, Roberta

AU - Amy Cheung, S Y

AU - Cullberg, Marie

AU - de Bruin, Elza C

AU - Koulai, Loumpiana

AU - Lindemann, Justin P O

AU - Pass, Martin

AU - Rugman, Paul

AU - Schiavon, Gaia

AU - Deb, Rahul

AU - Finlay, Pauline

AU - Foxley, Andrew

AU - Gee, Julia M W

PY - 2022/12/15

Y1 - 2022/12/15

U2 - 10.1158/1078-0432.CCR-22-3568

DO - 10.1158/1078-0432.CCR-22-3568

M3 - Comment/debate

C2 - 36519303

SN - 1078-0432

VL - 28

JO - Clinical cancer research : an official journal of the American Association for Cancer Research

JF - Clinical cancer research : an official journal of the American Association for Cancer Research

IS - 24

M1 - 5469

ER -

Robertson JFR, Coleman RE, Cheung KL, Evans A, Holcombe C, Skene A et al. Correction: Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER⁺ invasive breast cancer (STAKT). Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Dec 15;28(24):5469. doi: 10.1158/1078-0432.CCR-22-3568